Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method

被引:2
|
作者
Hirano, Ryohei [1 ]
Yokokawa, Akitomo [1 ]
Furihata, Tomomi [1 ]
Shibasaki, Hiromi [1 ,2 ]
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Pharm & Expt Therapeut, Tokyo, Japan
[2] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Pharm & Expt Therapeut, 1432-1 Horinouchi Hachioji, Tokyo 1920392, Japan
关键词
6; beta-hydroxycortisol; cortisol; CYP3A activity; endogenous biomarker; plasma concentration ratio; CYP3A ACTIVITY; ORAL MIDAZOLAM; INTERINDIVIDUAL VARIABILITY; 4-BETA-HYDROXYCHOLESTEROL; CLEARANCE; PROBE; ETHINYLESTRADIOL; PHARMACOKINETICS; PERFORMANCE; VALIDATION;
D O I
10.1111/bcp.15987
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: A less invasive evaluation method of cytochrome P450 3A (CYP3A) activity provides an important tool for personalized medicine. We aimed to clarify the usefulness of the plasma 6 beta-hydroxycortisol to cortisol concentration (6 beta-OHF/F) ratio as a minimally invasive CYP3A phenotyping method.Methods: Plasma 6 beta-OHF and cortisol concentrations were measured via liquid chromatography/tandem mass spectrometry. The plasma 6 beta-OHF/F ratio was compared with 6 beta-hydroxylation clearance of endogenous cortisol (CLm(6 beta); which we previously developed as an index of CYP3A activity) before, during and after oral contraceptive administration in 3 healthy women. The plasma 6 beta-OHF/F ratio was observed during oral clarithromycin administration. The plasma 6 beta-OHF/F ratio was also measured in 39 healthy participants.Results: The plasma 6 beta-OHF/F ratio in 3 healthy women on Day 21 of starting oral contraceptive administration decreased by 39, 49 and 61% compared with Day 0. These values were similar to CLm(6 beta) values (43, 54 and 59%, respectively). Plasma 6 beta-OHF/F ratio and CLm(6 beta) exhibited a good correlation (r = .9053). The 6 beta-OHF/F ratio decreased from 0.00921 to 0.00577 only 3 h following clarithromycin administration. The plasma 6 beta-OHF/F ratio ranged 0.00565-0.01556 in 39 healthy participants.Conclusion: Based on its close relationship with CLm(6 beta) and its decrease upon inhibition by clarithromycin, the plasma 6 beta-OHF/F ratio serves as an index of CYP3A activity. Using this minimally invasive index, we can identify patients with extremely low CYP3A activity before treatment initiation and optimize the initial drug dose, thereby mitigating the risk of severe adverse reactions.
引用
收藏
页码:1016 / 1026
页数:11
相关论文
共 50 条
  • [21] Interaction of cytochrome P450 3A inhibitors with P-glycoprotein
    Yasuda, K
    Lan, LB
    Sanglard, D
    Furuya, K
    Schuetz, JD
    Schuetz, EG
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (01): : 323 - 332
  • [22] Cloning, expression, and characterization of cytochrome P450 3A in minipig
    Soucek, P
    Anzenbacher, P
    Zuber, R
    Anzenbacherová, E
    Guengerich, FP
    TOXICOLOGY, 2001, 164 (1-3) : 146 - 146
  • [23] Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes
    Roberts, Jessica K.
    Moore, Chad D.
    Ward, Robert M.
    Yost, Garold S.
    Reilly, Christopher A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (02): : 308 - 316
  • [24] Cytochrome P450 3A polymorphisms and immunosuppressive drugs:: an update
    Anglicheau, Dany
    Legendre, Christophe
    Beaune, Philippe
    Thervet, Eric
    PHARMACOGENOMICS, 2007, 8 (07) : 835 - 849
  • [25] Expression of cytochrome P450 3A in leukocytes: Basis for a possible non-invasive test
    Mahnke, A
    Roos, PH
    Strotkamp, D
    Hanstein, WG
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (04) : 51 - 51
  • [26] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    Flockhart, DA
    Rae, JM
    PHARMACOGENOMICS JOURNAL, 2003, 3 (01): : 3 - 5
  • [27] EFFECT OF CANNABIDIOL (CBD) ON CYTOCHROME P450 3A IN THE MOUSE
    BORNHEIM, LM
    EVERHART, ET
    LI, J
    FASEB JOURNAL, 1993, 7 (03): : A265 - A265
  • [28] Estrogen regulation of the cytochrome P450 3A subfamily in humans
    Williams, ET
    Leyk, M
    Wrighton, SA
    Davies, PJA
    Loose, DS
    Shipley, GL
    Strobel, HW
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (02): : 728 - 735
  • [29] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    D A Flockhart
    J M Rae
    The Pharmacogenomics Journal, 2003, 3 : 3 - 5
  • [30] How important is intestinal cytochrome P450 3A metabolism?
    van Herwaarden, Antonius E.
    van Waterschoot, Robert A. B.
    Schinkel, Alfred H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (05) : 223 - 227